This study evaluates the hypothesis that the gas mixture with xenon will have a positive effect on the symptoms in patients with Parkinson's Disease. The study will test the hypothesis that the gas mixture with xenon has a symptomatic treatment potential for patients with Parkinson's Disease, as measured by change from baseline in the Unified Parkinson Disease Rating Scale (UPDRS).
Full Title of Study: “Comparative Controlled Study of Analgesic, Antiasthenic and Anti-Anxiety Effects of Xenon in Patients With Parkinson’s Disease”
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: November 2021
- Drug: NBTX-001
- Active drug group will receive 6 doses of NBTX-001 given three times a week.
- Drug: Standard of Care
- Placebo group will receive reconstituted air given three times a week.
Arms, Groups and Cohorts
- Experimental: NBTX-001
- 30% medical grade xenon/70% Oxygen
- Placebo Comparator: Standard of Care
- Reconstituted air
Clinical Trial Outcome Measures
- Unified Parkinson Disease Rating Scale (UPDRS)
- Time Frame: Baseline to Week 24
- Analysis of Unified Parkinson Disease Rating Scale (UPDRS) from baseline.The UPDRS scale refers to Unified Parkinson Disease Rating Scale, and it is a rating tool used to gauge the course of Parkinson’s disease in patients. The UPDRS scale includes series of ratings for typical Parkinson’s symptoms that cover all of the movement hindrances of Parkinson’s disease. The UPDRS scale consists of the following five segments: 1) Mentation, Behavior, and Mood, 2) ADL, 3) Motor sections, 4) Modified Hoehn and Yahr Scale, and 5) Schwab and England ADL scale. Each answer to the scale is evaluated by a medical professional that specializes in Parkinson’s disease during patient interviews. Some sections of the UPDRS scale require multiple grades assigned to each extremity with a possible maximum of 199 points. A score of 199 on the UPDRS scale represents the worst (total disability) with a score of zero representing (no disability).
Participating in This Clinical Trial
- The patient must be male or female over the age of 18.
- The subject must have idiopathic Parkinson's disease.
- The subject has Stage III by Hoehn and Yahr in the "on" state on a screening visit
- Subjects suffering from anxiety, depression, cognitive dysfunction
- Dopaminergic drugs should be taken in a stable dosage for 28 days prior to registration, and throughout the study
- Patients who have signed an approved consent form and are consistent with both the clinical trial plan and follow-up.
- Patients have atypical parkinsonism (eg, neuroleptics, metoclopramide, flunarizin), metabolic neurodegenerative disorders (eg, Wilson's disease), encephalitis, cerebrovascular disease or degenerative disease (e.g. progressive supranuclear palsy)
- Patients who received deep brain stimulation
- Patients with cancer, HIV, kidney or liver disease.
- Patients taking new antipsychotic, antidepressant, anxiolytic or narcotic drugs for less than 3 months
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- Nobilis Therapeutics Inc.
- Provider of Information About this Clinical Study
- Overall Contact(s)
- Vlad Bogin, MD, FACP, 971-229-1679, email@example.com
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.